Posted by Michael Wonder on 13 Jun 2023
Planned revision of EU pharmaceutical legislation: early market access and robust evidence need not remain a contradiction in terms
13 June 2023 - On 26 April, the EU Commission presented a proposal for the revision of pharmaceutical legislation in the European Union, on which IQWiG is now voting.
The EU Commission's declared goal is to improve access to innovative medicines across the EU at national level. On the one hand, there are still considerable differences between the countries, according to the reform proposal. In addition, drug development has so far only been based on actual needs to a limited extent. According to the IQWiG, the latter coincides with the care perspective, according to which a new drug is innovative if it improves care - i.e. offers patients added value compared to the therapy options available to date.
